High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

Zaman, Shakila; Aamir, Khalida; Hanson, Lars Å.; Lange, Stefan

doi:10.1016/j.ijid.2018.03.015

Cited by 11 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The parameters for optimal administration/uptake of Salovum® were established within the scope of a pilot study demonstrating an association between an increase of AF levels in blood after rectal administration of Salovum®, with a simultaneous reduction in ICP. In conformity with previous clinical studies investigating the antisecretory and anti-inflammatory actions of AF under various pathological conditions, no systemic side effects that could be attributed to Salovum® treatment were observed in any of the included patients [10,20,27,28]. The outcomes suggest that AF as an add-on therapy may, directly or indirectly, have some suppressive influence on edema-induced, intracranial hypertension.…”

Section: Discussionsupporting

confidence: 85%

“…AF-16 can bypass the blood-brain barrier after iv and intranasal administration and is detected both in cerebral tissue and CSF [1,17]. In clinical settings, Salovum® has only been utilized orally in awake patients for treatment of various inflammatory conditions [10,27,28]. The uptake of AF for achieving a clinical response after oral administration is dependent on a functioning gastrointestinal passage [20].…”

Section: Discussionmentioning

confidence: 99%

“…The spray dried egg yolk powder Salovum®, which has been classified as food for specific medical purposes by the European Union, is the only commercially available form of AF for clinical use. Salovum® has only been utilized for peroral administration in awake patients mainly suffering from various forms of intestinal, inflammatory disease [10,27,28]. In the present study, Salovum® administration was initiated if ICP was elevated above levels of 20 mm Hg for more than 1 h. The treatment was supplied for a minimum of 2 days as an add-on therapy to the conventional NICU management with optimized ventilation, sedation, analgesia, and maintenance of fluid balance.…”

Section: Af Administrationmentioning

confidence: 99%

“…Salovum® was administered every 8 h during two (patients 1, 2, and 3) to three (patient 4) days. The dosage of Salovum® and the interval for administration were determined based on experiences from previous human trials for oral administration of Salovum® [10,27].…”

Section: Af Administrationmentioning

confidence: 99%

See 3 more Smart Citations

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Control of intracranial pressure (ICP) is a key element in neurointensive care for directing treatment decisions in patients with severe traumatic brain injury (TBI). The anti-inflammatory protein antisecretory factor (AF) has been demonstrated to reduce experimentally induced high ICP in animal models. This report describes the first steps to investigate the uptake, safety, and influence of AF for reduction of elevated ICP in patients with TBI in a clinical setting. Method Four patients with severe TBI (Glasgow Coma Scale < 9) that required neurointensive care with ICP monitoring due to signs of refractory intracranial hypertension were investigated. One hundred milliliters of Salovum®, a commercially available egg yolk powder with high contents of AF peptides, was administrated either via nasogastric (patients 1 and 2) or rectal tube (patients 2, 3, and 4) every 8 h for 2 to 3 days as a supplement to the conventional neurointensive care. ICP was registered continuously. Plasma levels of AF were measured by enzyme-linked immunosorbent assay (ELISA) to confirm that Salovum® was absorbed appropriately into the bloodstream. Results In the first two patients, we observed that when delivered by the nasogastric route, there was an accumulation of the Salovum® solution in the stomach with difficulties to control ICP due to impaired gastric emptying. Therefore, we tested to administer Salovum® rectally. In the third and fourth patients, who both showed radiological signs of extensive brain edema, ICP could be controlled during the course of rectal administration of Salovum®. The ICP reduction was statistically significant and was accompanied by an increase in blood levels of AF. No adverse events that could be attributed to AF treatment or the rectal approach for Salovum® administration were observed. Conclusions The outcomes suggest that AF can act as a suppressor of high ICP induced by traumatic brain edema. Use of AF may offer a new therapeutic option for targeting cerebral edema in clinical practice. Keywords Traumatic brain injury. Brain edema. Intracranial hypertension. Antisecretory factor. Salovum®. AF-16 ELISA This article is part of the Topical Collection on Brain trauma

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Af Administrationmentioning

confidence: 99%

Section: Af Administrationmentioning

confidence: 99%

See 2 more Smart Citations

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Endogenous plasma and human milk levels of active AF can be increased by enterotoxins and by certain food constituents (Johansson et al, 2019). Active AF can be induced in both plasma and human milk by oral intake of specially processed cereals (Lange & Lönnroth, 2001;Svensson et al, 2004) or by drinking spraydried egg-yolk powder with a high content of AF-peptides (Zaman et al, 2018). Increase of endogenous AF synthesis improves the clinical outcome in diseases characterized by inflammation and secretory dysfunction (Zaman et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Changes in Antisecretory Factor in Human Milk During the Postpartum and Length of Gestation

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Preterm infants are more susceptible to inflammatory complications than term infants. Human milk contains numerous bioactive components protecting the newborn infant. Antisecretory factor, a protein regulating secretory and inflammatory processes by complex binding with complement factors, is present in human milk. Research Aims To describe antisecretory factor (1) in mother’s own milk in term and preterm infants; and (2) in donor milk before and after Holder pasteurization. Methods The study was prospective, longitudinal, explorative, and descriptive. Antisecretory factor-compleasome was determined using sandwich enzyme-linked immunosorbent assay in longitudinal human milk samples over 12 weeks from mothers ( N = 87) of term ( n = 41) and of preterm ( n = 46) infants and 20 anonymized donor human milk samples before and after Holder pasteurization. Results Antisecretory factor-compleasome was overall higher in colostrum versus mature milk ( p < .001) and no difference was found in term or preterm colostrum ( p = .82). In mature milk, compleasome was higher and more variable in the preterm group ( p = .01). After Holder pasteurization, compleasome levels increased ( p < .001). Conclusion Antisecretory factor followed the pattern of other immunological factors with high levels in colostrum. After preterm birth, levels of antisecretory factor were higher and more variable in mature milk. Holder pasteurization did not degrade antisecretory factor, indicating preserved anti-inflammatory properties in donor human milk.

show abstract

Antisecretory Factor 16 (AF16): A Promising Avenue for the Treatment of Traumatic Brain Injury—An In Vitro Model Approach

Vahrmeijer,

Kriel,

Harrington

et al. 2024

J Mol Neurosci

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is caused by an external mechanical force to the head, resulting in abnormal brain functioning and clinical manifestations. Antisecretory factor (AF16) is a potential therapeutic agent for TBI treatment due to its ability to inhibit fluid secretion and decrease inflammation, intracranial pressure, and interstitial fluid build-up, key hallmarks presented in TBI. Here, we investigated the effect of AF16 in an in vitro model of neuronal injury, as well as its impact on key components of the autophagy pathway and mitochondrial dynamics. N2Awt cells were treated with AF16, injured using a scratch assay, and analysed using confocal microscopy, correlative light and electron microscopy (CLEM), flow cytometry, and western blotting. Our results reveal that AF16 enhances autophagy activity, regulates mitochondrial dynamics, and provides protection as early as 6 h post-injury. Fluorescently labelled AF16 was observed to localise to lysosomes and the autophagy compartment, suggesting a role for autophagy and mitochondrial quality control in conferring AF16-associated neuronal protection. This study concludes that AF16 has potential as a therapeutic agent for TBI treatment through is regulation of autophagy and mitochondrial dynamics.

show abstract

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

Abstract: Peroral high doses of Salovum® rapidly and safely counteract diarrhea in children followed by a diarrhea-free period of 6 weeks.

Cited by 11 publications

References 21 publications

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

Changes in Antisecretory Factor in Human Milk During the Postpartum and Length of Gestation

Antisecretory Factor 16 (AF16): A Promising Avenue for the Treatment of Traumatic Brain Injury—An In Vitro Model Approach

Contact Info

Product

Resources

About